Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 7/20 | 0.35 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104341 | 1.00 | TRHR (0.37) | TRHRGLP1RTRHDECPB2P4HB | |
| SCHEMBL7098748 | 0.94 | YAP1 (0.34) | TRHRGLP1RTRHDEP4HBYAP1 | |
| SCHEMBL7098746 | 0.94 | YAP1 (0.34) | TRHRGLP1RTRHDEP4HBYAP1 | |
| SCHEMBL7099517 | 0.90 | TRHDE (0.40) | TRHRTRHDECPB2CPB1 | |
| SCHEMBL7099521 | 0.90 | TRHDE (0.40) | TRHRTRHDECPB2CPB1 | |
| SCHEMBL7104066 | 0.86 | NPSR1 (0.38) | TRHRTRHDEYAP1 | |
| SCHEMBL7104061 | 0.86 | NPSR1 (0.38) | TRHRTRHDEYAP1 | |
| SCHEMBL7103872 | 0.82 | TRHR (0.41) | TRHRTRHDECPB2CPB1 | |
| SCHEMBL7103875 | 0.82 | TRHR (0.41) | TRHRTRHDECPB2CPB1 | |
| SCHEMBL7099203 | 0.80 | TRHR (0.48) | TRHRTRHDECPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | TRHR 4768/4885GLP1R 3655/4885TRHDE 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.